Optimizing Treatment Approaches for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The use of targeted therapies as a preferred treatment approach for newly diagnosed chronic lymphocytic leukemia (CLL) has significantly transformed the treatment landscape of relapsed/refractory disease. Clinicians are challenged to remain up-to-date about the recent clinical advances that can help them make informed clinical decisions for individual patients to optimize clinical outcomes.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Minimal Residual Disease Assessment in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Is it Ready for Routine Clinical Practice?
There is a continuing need to educate clinicians about the current methods used for the detection of MRD and the prognostic significance of undetectable MRD in patients with CLL. This will also aid in the successful implementation of MRD testing when it becomes readily accessible for use in routine clinical setting.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Optimizing Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
Educating clinicians about the recent clinical advances is essential since this will aid in making informed clinical decisions to optimize the treatment for relapsed/refractory CLL/SLL.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022
These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Applying Guideline Updates and Real-World Experience in CLL: Experts Review State-of-the-Art Evidence and Address Clinical Challenges
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with CLL/SLL.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Application of Individualized Treatment Strategies for CLL/SLL
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with CLL/SLL.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation